Brokers Offer Predictions for Enovis Co.’s FY2023 Earnings (NYSE:ENOV)
Enovis Co. (NYSE:ENOV – Get Rating) – Equities researchers at KeyCorp lowered their FY2023 earnings per share estimates for Enovis in a research report issued on Monday, December 12th. KeyCorp analyst M. Mishan now anticipates that the company will earn $2.40 per share for the year, down from their previous forecast of $2.72. The consensus estimate for Enovis’ current full-year earnings is $2.24 per share.
Other analysts have also issued reports about the company. Jefferies Financial Group began coverage on Enovis in a research note on Wednesday, October 12th. They issued a “buy” rating and a $60.00 target price for the company. Canaccord Genuity Group began coverage on Enovis in a research report on Monday, September 12th. They issued a “buy” rating and a $67.00 price objective for the company. TheStreet lowered Enovis from a “c” rating to a “d” rating in a research report on Wednesday, November 2nd. Evercore ISI began coverage on Enovis in a research report on Monday, September 12th. They issued an “outperform” rating and a $68.00 price objective for the company. Finally, Wells Fargo & Company reduced their target price on Enovis from $60.00 to $53.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 26th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average price target of $63.50.
Enovis Stock Performance
Shares of NYSE:ENOV opened at $55.63 on Wednesday. Enovis has a twelve month low of $43.88 and a twelve month high of $142.82. The firm has a market cap of $3.01 billion, a PE ratio of 115.90, a price-to-earnings-growth ratio of 1.14 and a beta of 2.05. The business has a fifty day moving average of $51.45 and a 200-day moving average of $54.29.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new position in shares of Enovis during the 2nd quarter worth approximately $333,199,000. Cooke & Bieler LP acquired a new position in shares of Enovis during the 2nd quarter worth approximately $86,274,000. State Street Corp acquired a new position in shares of Enovis during the 2nd quarter worth approximately $72,935,000. Eminence Capital LP acquired a new position in shares of Enovis during the 2nd quarter worth approximately $66,263,000. Finally, Millennium Management LLC acquired a new position in shares of Enovis during the 2nd quarter worth approximately $52,132,000. Institutional investors and hedge funds own 89.40% of the company’s stock.
Insider Buying and Selling at Enovis
In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total value of $3,679,838.18. Following the sale, the executive vice president now owns 75,731 shares in the company, valued at approximately $4,133,397.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.30% of the company’s stock.
Enovis Company Profile
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enovis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Enovis wasn’t on the list.
While Enovis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
